Trials / Completed
CompletedNCT04466514
A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029
A Phase 1, 3-Way Crossover Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Astex Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Open-label, single dose, randomized, three-period, crossover design study to evaluate the effect of food on the bioavailability of a single oral dose of ASTX029 in healthy adult male and female participants. Following a screening period of up to 28 days, eligible participants will be enrolled and randomized to receive a single treatment (A, B, C) in a random order, with each treatment separated by an approximate 5-day washout period. The duration of the study is expected to be approximately 42 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASTX029 | Form: tablet; Route of Administration: oral |
Timeline
- Start date
- 2020-07-23
- Primary completion
- 2020-10-01
- Completion
- 2020-10-06
- First posted
- 2020-07-10
- Last updated
- 2024-08-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04466514. Inclusion in this directory is not an endorsement.